Trial to compare two Genentech drugs

02/22/2007 | Wall Street Journal, The

Genentech is urging doctors to use its Lucentis drug to treat age-related macular degeneration, but some doctors choose to use Genentech's cancer drug Avastin instead, even though Avastin is not FDA-approved to treat eye problems. The federal government is stepping in by conducting an NIH-funded comparison trial of the two biotech drugs. BIO argues that the NIH should study cutting-edge science rather than spend money to compare two approved drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX